Nelson George E, Mave Vidya, Gupta Amita
Division of Infectious Diseases, The Johns Hopkins University School of Medicine, 1830 East Monument Street Suite 450B, Baltimore, MD 21287, USA.
Division of Infectious Diseases, The Johns Hopkins University School of Medicine, 1830 East Monument Street Suite 450B, Baltimore, MD 21287, USA ; BJMC Clinical Trials Unit, BJ Medical College and Sassoon General Hospitals, Jai Prakash Narayan Road, Pune 411 001, India.
Biomed Res Int. 2014;2014:264351. doi: 10.1155/2014/264351. Epub 2014 Mar 19.
Sepsis is a serious infection and still a common cause of morbidity and mortality in resource-limited settings such as India. Even when microbiologic diagnostics are available, bacteremia is only identified in a proportion of patients who present with sepsis and bloodstream infections. Biomarkers have been used in a variety of disease processes and can help aid in diagnosing bacterial infections. There have been numerous biomarkers investigated to aid with diagnosis and prognostication in sepsis with the majority suffering from lack of sensitivity or specificity. Procalcitonin has been heralded as the biomarker that holds the most promise for bloodstream infections. Data are emerging in India, and in this review, we focus on the current data of biomarkers in sepsis with particular attention to how biomarkers could be used to augment diagnosis and treatment in India.
脓毒症是一种严重的感染，在印度等资源有限的地区仍是发病和死亡的常见原因。即使有微生物诊断方法，也只有一部分出现脓毒症和血流感染的患者能被确诊为菌血症。生物标志物已被应用于多种疾病过程，有助于诊断细菌感染。为了辅助脓毒症的诊断和预后评估，人们研究了众多生物标志物，但大多数都存在敏感性或特异性不足的问题。降钙素原被誉为对血流感染最具前景的生物标志物。印度也出现了相关数据，在本综述中，我们重点关注脓毒症生物标志物的当前数据，尤其关注生物标志物如何用于加强印度的诊断和治疗。
